Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$3.4 million.

  • Regenxbio's Other Working Capital Changes fell 12339.03% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 45592.4%. This contributed to the annual value of -$8.1 million for FY2024, which is 17664.52% down from last year.
  • As of Q3 2025, Regenxbio's Other Working Capital Changes stood at -$3.4 million, which was down 12339.03% from -$2.1 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Other Working Capital Changes ranged from a high of $39.8 million in Q1 2025 and a low of -$11.3 million during Q2 2024
  • Its 5-year average for Other Working Capital Changes is $2.3 million, with a median of -$805000.0 in 2023.
  • In the last 5 years, Regenxbio's Other Working Capital Changes surged by 131678.0% in 2021 and then tumbled by 217282.91% in 2022.
  • Over the past 5 years, Regenxbio's Other Working Capital Changes (Quarter) stood at $1.2 million in 2021, then plummeted by 175.49% to -$924000.0 in 2022, then tumbled by 227.6% to -$3.0 million in 2023, then skyrocketed by 31.88% to -$2.1 million in 2024, then crashed by 64.89% to -$3.4 million in 2025.
  • Its Other Working Capital Changes was -$3.4 million in Q3 2025, compared to -$2.1 million in Q2 2025 and $39.8 million in Q1 2025.